Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Neck scan could predict heart attacks in arthritis patients

NCT ID NCT07611747

Prevention Sponsor: Instituto de Investigación Marqués de Valdecilla Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using a carotid ultrasound (a neck scan) to find hidden plaque in arteries can help prevent heart attacks and strokes in people with inflammatory rheumatic diseases like rheumatoid arthritis or lupus. About 1,944 participants aged 50 and older will be split into two groups: one gets the ultrasound and, if plaque is found, receives high-dose statins; the other gets standard care. The goal is to see if this approach lowers major heart events over 4 years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
High-intensity statins (atorvastatin or rosuvastatin)
What this could lead to
If successful, this could provide a better way to identify and treat heart disease risk in people with inflammatory rheumatic diseases, potentially preventing heart attacks and strokes.
What could go wrong
This is a Phase 4 trial, but it is still ongoing and results are not yet known. The strategy may not reduce heart events as hoped, and statins can cause side effects like muscle pain or liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 1,944 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients aged ≥50 years who have provided written informed consent. 2. Fulfillment of classification criteria for at least one of the following inflammatory rheumatic diseases: * Rheumatoid arthritis (RA) according to ACR/EULAR 2010 criteria * Psoriatic arthritis (PsA) according to CASPAR criteria * Axial spondyloarthritis (AxSpA) according to ASAS criteria * Systemic lupus erythematosus (SLE) according to ACR/EULAR 2019 criteria 3. Low-to-moderate cardiovascular risk according to SCORE2/OP classification. Exclusion Criteria: 1. Presence of previous cardiovascular events, type 2 diabetes mellitus, familial hypercholesterolemia, or chronic kidney disease resulting in classification as high or very high cardiovascular risk. 2. Prior carotid ultrasound examination with subsequent therapeutic intervention derived from its results, either in the context of a research study or routine clinical practice. 3. Contraindications to lipid-lowering therapy, including recent history of alcoholism, active liver disease, or unexplained and persistent elevation of serum transaminases exceeding three times the upper limit of normal (applicable to statins and ezetimibe).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherosclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atherosclerosis cardiovascular disorder carotid artery disorder psoriatic arthritis rheumatoid arthritis spondyloarthropathy systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atherosclerosis Axial spondy Caridovascular disease Carotid artery diseases Psoriatic arthritis (PSA) Rheumatoid arthritis (RA Systemic lupus erythematosus (SLE)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    17 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hispital Universitario Virgen de la Arrixaca

    NOT_YET_RECRUITING

    Murcia, Murcia, Spain

  • Hospital General Universitario de Alicante

    RECRUITING

    Alicante, Alicante, Spain

  • Hospital General Universitario de Ciudad Real

    NOT_YET_RECRUITING

    Ciudad Real, Ciudad Real, Spain

  • Hospital Sierrallana

    RECRUITING

    Torrelavega, Cantabria, Spain

  • Hospital Universitari Son LLàtzer

    NOT_YET_RECRUITING

    Palma, Isla Baleares, Spain

  • Hospital Universitario Araba

    RECRUITING

    Vitoria-Gasteiz, Álava, Spain

  • Hospital Universitario La Paz

    NOT_YET_RECRUITING

    Madrid, Madrid, Spain

  • Hospital Universitario Marqués de Valdecilla

    NOT_YET_RECRUITING

    Santander, Cantabria, Spain

  • Hospital Universitario Ramón y Cajal

    NOT_YET_RECRUITING

    Madrid, Madrid, Spain

  • Hospital Universitario Reina Sofía

    NOT_YET_RECRUITING

    Córdoba, Córdoba, Spain

  • Hospital Universitario Vall d'Hebrón

    RECRUITING

    Barcelona, Barcelona, Spain

  • Hospital Universitario de Basurto

    RECRUITING

    Bilbao, Vizcaya, Spain

  • Hospital Universitario de Canarias

    NOT_YET_RECRUITING

    San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain

  • Hospital Universitario de Elche

    NOT_YET_RECRUITING

    Elche, Alicante, Spain

  • Hospital Universitario de Gran Canaria Dr. Negrín

    NOT_YET_RECRUITING

    Las Palmas de Gran Canaria, Las Palmas, Spain

  • Hospital Vega Baja de Orihuela

    RECRUITING

    Orihuela, Alicante, Spain

  • Hospital de Laredo

    RECRUITING

    Laredo, Cantabria, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.